183 related articles for article (PubMed ID: 17237004)
1. [An update on recent developments in non-Hodgkin's lymphoma].
Bouabdallah K; Milpied N
Bull Cancer; 2007 Jan; 94(1):43-52. PubMed ID: 17237004
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
4. Diffuse aggressive lymphoma.
Fisher RI; Miller TP; O'Connor OA
Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
6. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian approach to a patient with a residual mass after treatment for non-Hodgkin's lymphoma of the thyroid.
Bibb J; Hromas R; Rabinowitz I
J Clin Oncol; 2005 Dec; 23(34):8911-3. PubMed ID: 16314654
[No Abstract] [Full Text] [Related]
8. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM
Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
[TBL] [Abstract][Full Text] [Related]
9. False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.
Inoue Y; Tamaki H; Yamagami T; Iwasaki H; Nakatsuka S; Soma T
Eur J Haematol; 2007 Jul; 79(1):88-90. PubMed ID: 17532762
[No Abstract] [Full Text] [Related]
10. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.
Han HS; Escalón MP; Hsiao B; Serafini A; Lossos IS
Ann Oncol; 2009 Feb; 20(2):309-18. PubMed ID: 18842613
[TBL] [Abstract][Full Text] [Related]
11. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly.
Coiffier B
Semin Oncol; 2003 Feb; 30(1 Suppl 2):21-7. PubMed ID: 12652461
[TBL] [Abstract][Full Text] [Related]
12. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
Boye J; Elter T; Engert A
Ann Oncol; 2003 Apr; 14(4):520-35. PubMed ID: 12649096
[TBL] [Abstract][Full Text] [Related]
13. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
Hernandez MC; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1274-87. PubMed ID: 15275710
[TBL] [Abstract][Full Text] [Related]
14. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Czuczman MS
Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
[TBL] [Abstract][Full Text] [Related]
15. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
[TBL] [Abstract][Full Text] [Related]
16. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin's and non-Hodgkin's lymphomas.
Rademaker J
Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
[TBL] [Abstract][Full Text] [Related]
18. Non-Hodgkin's lymphoma: present status and future prospects.
Habermann TM
Hosp Pract (1995); 1999 Dec; 34(13):81-4, 87-8. PubMed ID: 10611900
[TBL] [Abstract][Full Text] [Related]
19. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M; Schubert J; Ziepert M; Schmits R; Mohren M; Lengfelder E; Reiser M; Nickenig C; Clemens M; Peter N; Bokemeyer C; Eimermacher H; Ho A; Hoffmann M; Mertelsmann R; Trümper L; Balleisen L; Liersch R; Metzner B; Hartmann F; Glass B; Poeschel V; Schmitz N; Ruebe C; Feller AC; Loeffler M;
Lancet Oncol; 2008 Feb; 9(2):105-16. PubMed ID: 18226581
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]